Carcinoma  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

32 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00075647: CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed
2
40
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
03/05
 
NCT00028028: CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed
2
80
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Cancer
01/07
 
NCT00079235: CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer

Checkmark P2 Data
Jun 2012 - Jun 2012: P2 Data
Completed
2
50
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
06/07
 
NCT00574483: Treatment of Advanced Renal Cell Carcinoma With Quinacrine

Withdrawn
2
0
US
quinacrine, CBLC102
Cleveland BioLabs
Renal Cell Carcinoma
01/08
01/08
NCT00072176: Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Checkmark In women with recurrent or metastatic endometrial cancer
Aug 2013 - Aug 2013: In women with recurrent or metastatic endometrial cancer
Checkmark P2 data
Jul 2011 - Jul 2011: P2 data
Completed
2
62
Canada
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma, Stage IIIA Endometrial Carcinoma, Stage IIIB Endometrial Carcinoma, Stage IIIC Endometrial Carcinoma, Stage IVA Endometrial Carcinoma, Stage IVB Endometrial Carcinoma
05/09
08/09
NCT01079767 / 2009-014443-36: Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis

Terminated
2
6
Europe
temsirolimus
Federation Francophone de Cancerologie Digestive
Liver Cancer
12/10
 
NCT00093782: Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Completed
2
36
Canada
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma
04/11
04/11
NCT00494091: Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

Checkmark P2 data
Jul 2012 - Jul 2012: P2 data
Completed
2
82
Japan, RoW
Temsirolimus (CCI-779), Torisel
Pfizer
Advanced Renal Cell Carcinoma
05/11
03/12
TORAVA, NCT00619268 / 2007-003369-42: Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Checkmark P2 data
Jun 2011 - Jun 2011: P2 data
Checkmark P2 data
More
Completed
2
160
Europe
Temsirolimus, Torisel®, Bevacizumab, Avastin®, Sunitinib, Sutent®, Interferon alpha-2a, Roféron®
Centre Leon Berard
Metastatic Renal Cell Carcinoma
02/12
02/12
TEMHEAD, NCT01172769: Efficacy Study of Temsirolimus to Treat Head and Neck Cancer

Checkmark ECCO-ESMO-ESTRO 2013
Sep 2013 - Sep 2013: ECCO-ESMO-ESTRO 2013
Checkmark P2 data - ESMO 2012
Sep 2012 - Sep 2012: P2 data - ESMO 2012
Completed
2
42
Europe
Temsirolimus, Torisel, mTOR inhibitor, protein kinase inhibitor
Hannover Medical School
Head and Neck Squamous Cell Carcinoma
03/12
03/12
NCT00979966 / 2009-010143-13: Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib

Completed
2
22
Europe
Temsirolimus, Sunitinib
Central European Society for Anticancer Drug Research
Non-clear Cell Renal Cell Cancer
07/12
 
NCT01026792: Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery

Checkmark
May 2013 - May 2013: 
Completed
2
38
Canada
Temsirolimus, CCI-779, Torisel, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
08/12
11/12
NCT01009203: Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Checkmark Torisel+Tarceva
Feb 2013 - Feb 2013: Torisel+Tarceva
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Terminated
2
13
US
Erlotinib, Tarceva, OSI-774, Temsirolimus, Torisel, CCI-779
New Mexico Cancer Care Alliance, Genentech, Inc.
Squamous Cell Carcinoma
09/12
12/12
MAESTRO HN, NCT01256385: Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
86
US, RoW
Cetuximab, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Verrucous Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Oral Cavity Verrucous Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Verrucous Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Oral Cavity Verrucous Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
12/13
12/13
NCT00378703: Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Checkmark ASCO-GU 2013
Feb 2013 - Feb 2013: ASCO-GU 2013
Completed
2
361
US, RoW
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
02/14
03/17
SERCC, NCT01342627 / 2010-019726-14: Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma

Terminated
2
4
Europe
Sorafenib, Nexavar
Centro di Riferimento Oncologico - Aviano
Metastatic Renal Cell Carcinoma
09/14
09/15
NCT00782275: Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
41
US
bevacizumab, avastin, temsirolimus, torisel
Beth Israel Deaconess Medical Center, Genentech, Inc., Dana-Farber Cancer Institute, Brigham and Women's Hospital, Vanderbilt University Medical Center
Renal Cell Carcinoma, Kidney Cancer
05/15
05/15
NCT00923845: Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Completed
2
25
US
Pentostatin, Nipent, Sirolimus, Rapamune, Cyclophosphamide, Cytoxan, Allogeneic Hematopoietic Stem Cell Transplant (HSCT), Th2 rapa cells, Donor Lymphocyte Harvest, Induction Therapy, GVHD prophylaxis, Donor Hematopoietic Stem Cell Harvest
National Cancer Institute (NCI)
Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome
06/15
06/17
NCT01460979: Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
47
Europe
Temsirolimus
AGO Study Group
Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Endometrial Neoplasms
06/15
11/15
NCT01264341 / 2010-020664-38: Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

Terminated
2
39
Europe
Bevacizumab, Temsirolimus
Hellenic Cooperative Oncology Group
Kidney Cancer
07/15
07/15
PUMA-NER-4201, NCT01827267 / 2012-004743-68: Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Checkmark From HER2 mutant NSCLC
Sep 2014 - Sep 2014: From HER2 mutant NSCLC
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
62
US, Europe
neratinib, Nerlynx, temsirolimus, Torisel
Puma Biotechnology, Inc.
HER2-mutant Non-Small Cell Lung Cancer
09/16
10/17
NCT01010126: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Checkmark P2 data
More
Completed
2
252
Canada, US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
03/17
03/17
NCT02479490 / 2015-002419-14: PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI

Terminated
2
8
Europe
Prednisone + Everolimus, prednisone, everolimus
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Metastatic Renal Cancer
05/17
09/17
NCT02560012: Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Terminated
2
4
US
Sunitinib, Sutent, Temsirolimus, Torisel, Sorafenib, Nexavar, Pazopanib, Votrient, Everolimus, Afinitor, Axitinib, Inlyta
The University of Texas Health Science Center, Houston
Carcinoma, Renal Cell
07/17
07/17
NCT02122003: Second Line Sorafenib After Pazopanib in Patients With RCC

Terminated
2
16
Europe
Sorafenib, Nexavar
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Renal Cell Carcinoma
11/17
11/17
NCT00106353: Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Completed
1/2
71
US, Canada, Europe, RoW
Torisel, temsirolimus
Pfizer
Adenocarcinoma, Neoplasms
10/09
01/12
CRUK-08/015, NCT01090466 / 2007-007615-82: Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Completed
1/2
15
Europe
cisplatin, gemcitabine hydrochloride, temsirolimus, pharmacological study
Cardiff University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
01/10
03/16
NCT01015664: Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Terminated
1/2
11
US
temsirolimus, Torisel, cisplatin, Platinol, cetuximab, Erbitux
University of Tennessee Cancer Institute, National Comprehensive Cancer Network
Squamous Cell Carcinoma of the Head and Neck
12/12
12/12
NCT00921310: Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

Terminated
1/2
12
US
Pemetrexed, Alimta, Temsirolimus, Torisel
Washington University School of Medicine
Carcinoma, Non-Small-Cell Lung
01/13
04/16
NCT01335074: Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Withdrawn
1/2
0
Europe
Temsirolimus + Sorafenib
Philipps University Marburg Medical Center
Hepatocellular Carcinoma
12/13
 
NCT01251458: Hepatocellular Carcinoma (HCC)_Torisel_

Completed
1/2
46
RoW
Torisel
Chinese University of Hong Kong
Inoperable HCC
01/16
01/16
NCT02423954: Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Checkmark WCGC 2016 - metastatic colon cancer and pancreatic adenocarcinoma
Jun 2016 - Jun 2016: WCGC 2016 - metastatic colon cancer and pancreatic adenocarcinoma
Terminated
1/2
33
US
Temsirolimus, Torisel, Irinotecan, Camptosar, Irinotecan + capecitabine, Camptosar + Xeloda, nivolumab, Opdivo
Western Regional Medical Center
Advanced Cancer, Pancreatic Cancer, Renal Cell Cancer, Non Small Cell Lung Cancer, Colorectal Carcinoma, Endometrial, Uterine
11/17
11/17

Download Options